NightHawk Biosciences, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey Alan Wolf
- Full Time Employees
- 77
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 627 Davis Drive Morrisville NC United States of America 27560
- IPO Date
- Jul 24, 2013
- CIK
- 0001476963
- Website
- nighthawkbio.com
- Similar Companies
- Business
- NightHawk Biosciences, Inc. (NHWK) operates as a clinical-stage biopharmaceutical company focused on the development, manufacturing, and commercialization of immunotherapies and medical countermeasures against infectious diseases and biological threats; its core products and services include ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for inhalational anthrax, cGMP biomanufacturing capabilities encompassing mammalian cell culture and microbial fermentation through its Scorpius BioManufacturing subsidiary, process development services such as cell therapy and downstream processing, bioanalytical services including immunoassays and molecular assays, and contract development and manufacturing organization (CDMO) offerings for biologics and large molecule therapeutics targeting biotech and pharmaceutical clients. Founded in 2008 and headquartered in Morrisville, North Carolina, with key manufacturing operations in San Antonio, Texas, the company serves government entities, research institutes, and biopharma firms primarily in the United States. In recent developments, NightHawk Biosciences divested its Elusys Therapeutics subsidiary and non-core assets in late 2023 to concentrate on its CDMO business, securing over $20 million in manufacturing contracts; announced a planned name change to Scorpius Holdings, Inc. in January 2024 with trading under SCPX commencing in February 2024; implemented cost optimization in 2025 including workforce reductions and facility consolidations for over $6 million in annualized savings; launched Scorpius Ventures for equity-based biotech partnerships aligned with U.S. onshoring initiatives; and explored halal-certified biomanufacturing expansion into Southeast Asia, particularly Malaysia.
Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University
Scorpius Holdings Accepted as a Member of the US Government's BioMaP-Consortium
Scorpius Holdings, Inc. Announces Closing of Public Offering
Scorpius Holdings, Inc. Announces Pricing of Public Offering
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023
NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today
NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note
NightHawk's Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO
NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company
NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets
NightHawk Biosciences Provides Q3 2023 Business Update
NightHawk Biosciences Provides Q2 2023 Business Update
Why Is NightHawk Biosciences (NHWK) Stock Up 26% Today?
Why NightHawk Biosciences Stock Is Soaring
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today